グルカゴン様ペプチド-1受容体アゴニストを標的とした多発性硬化症の治療 (TAG-MS)
グルカゴン様ペプチド-1受容体アゴニストを標的とした多発性硬化症治療(TAG-MS):第2相ランダム化二重盲検並行群間比較試験
The goal of this clinical trial is to evaluate if the study drug will reduce brain and retinal atrophy by reducing inflammation and subsequently slowing neurodegeneration in people with Multiple Sclerosis. The main outcome for the trial is change in normalized brain parenchymal volume (nBPV), measured by magnetic resonance imaging (MRI).
Researchers will compare outcomes from participants randomized to the study drug, versus participants randomized to placebo, to see if there are signs of slowed neurodegeneration (i.e., reduction in brain and retinal atrophy).
調査の概要
状態
状態
条件
条件
研究の種類
研究の種類
入学 (推定)
入学
段階
段階
- フェーズ2
連絡先と場所
研究連絡先
研究連絡先
- 名前:Study Manager
- 電話番号:667-306-8153
- メール:mvieira4@jh.edu
研究場所
-
-
Kansas
-
Kansas City、Kansas、アメリカ、66103
- 募集
- University of Kansas Medical Center
-
主任研究者:
- Sharon Lynch, MD
-
コンタクト:
- Sara Baker
- 電話番号:913-588-6937
- メール:sbaker12@kumc.edu
-
-
Maryland
-
Baltimore、Maryland、アメリカ、21287
- 募集
- Johns Hopkins University
-
主任研究者:
- Ellen Mowry, MD, MCR
-
コンタクト:
- Margaret Vieira
- 電話番号:667-306-8153
- メール:mvieira4@jh.edu
-
-
New York
-
New York、New York、アメリカ、10029
- 募集
- Mount Sinai School of Medicine
-
コンタクト:
- Susan Filomena
- 電話番号:212-241-4364
- メール:susan.e.filomena@mssm.edu
-
-
参加基準
適格基準
適格基準
就学可能な年齢
健康ボランティアの受け入れ
受講資格のある性別
説明
Inclusion Criteria:
- Diagnosis of MS (2024 criteria); clinically stable on MS therapy for ≥12 months without relapse or new lesions on brain MRI
- Aged 18-60 years
- Body mass index ≥27.0 kg/m2
Exclusion Criteria:
-
No GLP-1RA or GIP/GLP-1 RA in past year; no known hypersensitivity to medication class
-
No known Barrett's esophagus/gastroesophageal reflux disease, pancreatitis (including past), or gastroparesis
-
No personal/family history of medullary thyroid carcinoma or history of multiple endocrine neoplasia syndrome type 2
-
No chronic kidney disease (estimated glomerular filtration rate ≤50 mL/min) in past year, type 1 diabetes, known diabetic retinopathy, use of insulin or insulin-inducing medications*, dipeptidyl peptidase IV inhibitors**, or warfarin; current/active alcohol or illicit substance abuse
-
No concerns about candidacy of individual on part of person's neurologist or study team clinicians
-
Current or planned (next 2 years) pregnancy/breastfeeding; if able to become pregnant, agree to reliable contraception (contraception requirements as discussed below)***
- currently-approved: Lispro, Aspart, Glulisine, Afrezza, Regular, Concentrated Regular, or Novolin, Velosulin, NPH, glargine, detemir, degludec, and premixed; approved secretagogues: sulphonylureas (e.g. glipizide (± metformin), glyburide (± metformin), glimepiride, pioglitazone/glimepiride) & meglitinide analogues (nateglinide and repaglinide); ** currently-approved:sitagliptin, saxagliptin, linagliptin, alogliptin ***Contraception: Participants of childbearing potential (participant has a uterus and is pre-menopausal) must agree to use contraception, using either one method with a failure rate of <1%/year, or two methods of lesser effectiveness:
Contraceptive methods with a failure rate of < 1% per year includes the following:
- Combined (estrogen and progesterone containing) hormonal contraception (vaginal ring, birth control patch) or progesterone-only hormonal contraception (birth control injections, intrauterine device (IUD), or hormone-releasing implant), or copper IUD
- Complete abstinence from sexual encounters with a person who has testes
Those who do not wish to use one of the above methods of contraception must use two methods. Options include:
-
Oral hormonal contraception plus one barrier method during sexual encounter with a person who has testes (below). While typically oral hormonal contraception has a low failure rate, it is possible that the absorption of contraceptive pills taken by mouth will be impacted by the study drug and thus lower contraceptive effectiveness. Thus, people using pills as primary contraception must, during asexual encounter with a person who has testes, use a second form of barrier contraceptive (below) or must change to one of the other contraceptive methods listed above.
-
Two forms of barrier contraception during sexual encounter with a person who has testes. Examples of barrier contraceptive methods include the following:
-
A condom with or without spermicide
-
A cap, diaphragm, or sponge with or without spermicide
- Periodic abstinence (e.g., calendar, ovulation, symptothermal, or postovulation methods) and withdrawal are not acceptable methods of contraception.
-
研究計画
研究はどのように設計されていますか?
デザインの詳細
- 主な目的:処理
- 割り当て:ランダム化
- 介入モデル:並列代入
- マスキング:4倍
アーム数
武器と介入
参加者グループ / アーム参加者グループ / アーム |
介入・治療介入・治療 |
|---|---|
|
プラセボコンパレーター:プラセボ
|
Placebo (saline solution) |
|
アクティブコンパレータ:NLY01 (Study Drug)
5 mg subcutaneous weekly for the first 4 weeks, then 10 mg subcutaneous weekly, with pre-planned dose adjustments if adverse events prevent full dosage. |
NLY01 is a pegylated exenatide |
この研究は何を測定していますか?
主要な結果の測定
主要な結果の測定
結果測定 |
メジャーの説明 |
時間枠 |
|---|---|---|
|
Change in normalized (for head size) brain parenchymal volume (nBPV)
時間枠:Baseline, week 48, and week 96
|
Change in normalized (for head size) nBPV (mL). Measured from randomization to end of treatment (approximately 96 weeks). Presented as mean and standard deviation |
Baseline, week 48, and week 96
|
二次結果の測定
二次結果の測定
結果測定 |
メジャーの説明 |
時間枠 |
|---|---|---|
|
Change in normalized gray matter volume (mL)
時間枠:Baseline, week 48, and week 96
|
Presented as mean and standard deviation Measured from randomization to end of treatment (approximately 96 weeks). |
Baseline, week 48, and week 96
|
|
Change in thalamic volume (mL)
時間枠:Baseline, week 48, and week 96
|
Measured from randomization to end of treatment (up to 96 weeks). Presented as mean and standard deviation. |
Baseline, week 48, and week 96
|
|
Change in cortical thickness (mm)
時間枠:Baseline, week 48, and week 96
|
Measured from randomization to end of treatment (approximately 96 weeks), Presented as mean and standard deviation. |
Baseline, week 48, and week 96
|
|
Change in retinal nerve fiber layer thickness
時間枠:Baseline, week 48, and week 96
|
Measured in μm, from randomization to end of treatment (approximately 96 weeks), |
Baseline, week 48, and week 96
|
|
Change in ganglion cell/inner plexiform thickness
時間枠:Baseline, week 48, and week 96
|
Measured in μm, from randomization to end of treatment (approximately 96 weeks), |
Baseline, week 48, and week 96
|
|
Disability progression as assessed by the Expanded Disability Status Scale (EDSS)
時間枠:Approximately every 24 weeks, up to 96 weeks
|
Expanded Disability Status Scale (EDSS). Scale range 0-10; higher score is worse disability progression |
Approximately every 24 weeks, up to 96 weeks
|
|
Disability progression as assessed by the Multiple Sclerosis Functional Composite (MSFC)
時間枠:Approximately every 24 weeks, up to 96 weeks
|
The Multiple Sclerosis Functional Composite (MSFC) calculates a single Z-score from tests of ambulation, arm dexterity, and cognition. Scores are converted to a z score with a mean and standard deviation. A higher Z-score indicates better function. |
Approximately every 24 weeks, up to 96 weeks
|
|
Disability progression as assessed by the Expanded Disability Status Scale-Plus
時間枠:Approximately every 24 weeks, up to 96 weeks
|
The EDSS-plus allows for documentation of progression as a composite value, considering progression as having occurred if any one of the following occurs: 20% increase in timed 25-foot walk or 9-hole peg test, or a 1.0-point increase in EDSS (if baseline is 5.5 or less) or a 0.5-point increase (if baseline is >5.5). |
Approximately every 24 weeks, up to 96 weeks
|
|
Patient-reported disability progression as assessed by the Patient-Determined Disease Steps
時間枠:Approximately every 24 weeks, up to 96 weeks
|
Patient-Determined Disease Steps score range 0-8; higher is worse progression |
Approximately every 24 weeks, up to 96 weeks
|
|
Change in self-reported anxiety as assessed by the Quality of Life in Neurological Disorders (Neuro-QOL) Anxiety Subscale
時間枠:Approximately every 24 weeks, up to 96 weeks
|
Quality of Life in Neurological Disorders (Neuro-QOL) Anxiety Subscale. Higher scores indicate more of the domain; distribution of T-Score has a mean of 50, standard deviation of 10. |
Approximately every 24 weeks, up to 96 weeks
|
|
Change in self-reported depression as assessed by the Quality of Life in Neurological Disorders (Neuro-QOL) Depression Subscale
時間枠:Approximately every 24 weeks, up to 96 weeks
|
Quality of Life in Neurological Disorders (Neuro-QOL) Depression Subscale. Higher scores indicate more of the domain; distribution of T-Score has a mean of 50, standard deviation of 10. |
Approximately every 24 weeks, up to 96 weeks
|
|
Change in self-reported fatigue as assessed by the Quality of Life in Neurological Disorders (Neuro-QOL) Fatigue Subscale
時間枠:Approximately every 24 weeks, up to 96 weeks
|
Quality of Life in Neurological Disorders (Neuro-QOL) Fatigue Subscale. Higher scores indicate more of the domain; distribution of T-Score has a mean of 50, standard deviation of 10. |
Approximately every 24 weeks, up to 96 weeks
|
|
Change in self-reported upper extremity function as assessed by the Quality of Life in Neurological Disorders (Neuro-QOL) Upper Extremity Function Subscale
時間枠:Approximately every 24 weeks, up to 96 weeks
|
Quality of Life in Neurological Disorders (Neuro-QOL) Upper Extremity Function Subscale. Higher scores indicate more of the domain; distribution of T-Score has a mean of 50, standard deviation of 10. |
Approximately every 24 weeks, up to 96 weeks
|
|
Change in self-reported lower extremity function as assessed by the Quality of Life in Neurological Disorders (Neuro-QOL) Lower Extremity Function Subscale
時間枠:Approximately every 24 weeks, up to 96 weeks
|
Quality of Life in Neurological Disorders (Neuro-QOL) Lower Extremity Function Subscale. Higher scores indicate more of the domain; distribution of T-Score has a mean of 50, standard deviation of 10. |
Approximately every 24 weeks, up to 96 weeks
|
|
Change in self-reported cognitive function as assessed by the Quality of Life in Neurological Disorders (Neuro-QOL) Cognitive Function Subscale
時間枠:Approximately every 24 weeks, up to 96 weeks
|
Quality of Life in Neurological Disorders (Neuro-QOL) Cognitive Function Subscale. Higher scores indicate more of the domain; distribution of T-Score has a mean of 50, standard deviation of 10. |
Approximately every 24 weeks, up to 96 weeks
|
|
Change in positive affect/well-being as assessed by the Quality of Life in Neurological Disorders (Neuro-QOL) Positive Affect/Well-being Subscale
時間枠:Approximately every 24 weeks, up to 96 weeks
|
Quality of Life in Neurological Disorders (Neuro-QOL) Positive Affect/Well-being Subscale. Higher scores indicate more of the domain; distribution of T-Score has a mean of 50, standard deviation of 10. |
Approximately every 24 weeks, up to 96 weeks
|
|
Change in self-reported sleep disturbance as assessed by the Quality of Life in Neurological Disorders (Neuro-QOL) Sleep Disturbance Subscale
時間枠:Approximately every 24 weeks, up to 96 weeks
|
Quality of Life in Neurological Disorders (Neuro-QOL) Sleep Disturbance Subscale. Higher scores indicate more of the domain; distribution of T-Score has a mean of 50, standard deviation of 10. |
Approximately every 24 weeks, up to 96 weeks
|
|
Change in self-reported ability to participate in social roles Quality of Life in Neurological Disorders (Neuro-QOL) Ability to Participate in Social Roles Subscale
時間枠:Approximately every 24 weeks, up to 96 weeks
|
Quality of Life in Neurological Disorders (Neuro-QOL) Ability to Participate in Social Roles Subscale. Higher scores indicate more of the domain; distribution of T-Score has a mean of 50, standard deviation of 10. |
Approximately every 24 weeks, up to 96 weeks
|
|
Change in self-reported stigma as assessed by the Quality of Life in Neurological Disorders (Neuro-QOL) Stigma Subscale
時間枠:Approximately every 24 weeks, up to 96 weeks
|
Quality of Life in Neurological Disorders (Neuro-QOL) Stigma Subscale. Higher scores indicate more of the domain; distribution of T-Score has a mean of 50, standard deviation of 10. |
Approximately every 24 weeks, up to 96 weeks
|
|
Adverse events
時間枠:From randomization to week 96
|
Proportion of individuals in each arm experiencing adverse events |
From randomization to week 96
|
|
Serious adverse events
時間枠:From randomization to week 96
|
Proportion of individuals in each arm experiencing serious adverse events |
From randomization to week 96
|
協力者と研究者
協力者
協力者
捜査官
捜査官
- 主任研究者:Ellen M Mowry, MD, MCR、Johns Hopkins University
研究記録日
主要日程の研究
研究開始 (実際)
研究開始
一次修了 (推定)
一次修了
研究の完了 (推定)
研究の完了
試験登録日
最初に提出
最初に提出
QC基準を満たした最初の提出物
QC基準を満たした最初の提出物
最初の投稿 (実際)
最初の投稿
学習記録の更新
投稿された最後の更新 (実際)
投稿された最後の更新
QC基準を満たした最後の更新が送信されました
QC基準を満たした最後の更新が送信されました
最終確認日
最終確認日
詳しくは
本研究に関する用語
追加の関連 MeSH 用語
その他の研究ID番号
その他の研究ID番号
- IRB00454859
個々の参加者データ (IPD) の計画
個々の参加者データ (IPD) を共有する予定はありますか?
IPD プランの説明
De-identified individual participant data (IPD) that underlie the results reported in this publication, along with the protocol and analysis plan, will be available upon reasonable request to qualified researchers. Requests must include a proposal and are contingent on meeting regulatory approvals, including a signed data use agreement.
IPD 共有時間枠
Data will be available 6 months after publication and remain accessible for 12-24 months.
IPD 共有アクセス基準
Qualified researchers who have completed and signed approvals for data sharing.
IPD 共有サポート情報タイプ
- STUDY_PROTOCOL
- SAP
医薬品およびデバイス情報、研究文書
米国FDA規制医薬品の研究
米国FDA規制機器製品の研究
この情報は、Web サイト clinicaltrials.gov から変更なしで直接取得したものです。研究の詳細を変更、削除、または更新するリクエストがある場合は、register@clinicaltrials.gov。 までご連絡ください。 clinicaltrials.gov に変更が加えられるとすぐに、ウェブサイトでも自動的に更新されます。